knowledge -WSS

knowledge

author：comprehensive 2025-09-06 01:58:50 - browse：39111

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Generate Biomedicines machine learning biotech raises $273M

WSS

WATCH: Why do bright lights make us see spots?

FDA panel endorses Alnylam’s heart drug — after picking it apart

Some top drug companies are starting to take action on climate

Flu, Covid vaccination rates decline, new survey data show

Congress extends some pandemic preparedness programs

IVG is promising — but it won’t replace IVF quite yet

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Activists slam private health insurers over coverage restrictions

What will Novo Nordisk's VC do with its influx of cash?

New air purifier tech could be key to improving indoor air quality

IRA could hurt research into orphan drugs for rare diseases

Guidelines to prevent youth baseball injuries need more muscle

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

The cancer drug shortage isn’t new — and neither are the solutions

How housing is health care on Long Island

Activists slam private health insurers over coverage restrictions

New oral drug delivery patch is modeled after octopus tentacles

leisure time

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The stability of $0 premiums in Medicare Advantage

New weight loss drugs vying to be the next Wegovy or Mounjaro

Regeneron agrees to White House price limits on anti

FDA proposes changes to key medical devices approval pathway

Generate Biomedicines machine learning biotech raises $273M

hotspot

leisure time

explore

hotspot